NCT00002265View on ClinicalTrials.gov

An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Zalcitabine

Trial Locations (9)

19146

Graduate Hosp, Philadelphia

30308

AIDS Research Consortium of Atlanta, Atlanta

33125

Med Service, Miami

33308

Ctr for Special Immunology, Fort Lauderdale

33901

Dr Robert Swartz, Fort Myers

48202

Henry Ford Hosp, Detroit

75230

Humana Hosp / Med City Dallas, Dallas

94114

Davies Med Ctr, San Francisco

94115

Mount Zion Med Ctr, San Francisco

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00002265 - An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492 | Biotech Hunter | Biotech Hunter